These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 18723840)

  • 1. What is causing the reduced drug-placebo difference in recent schizophrenia clinical trials and what can be done about it?
    Kemp AS; Schooler NR; Kalali AH; Alphs L; Anand R; Awad G; Davidson M; Dubé S; Ereshefsky L; Gharabawi G; Leon AC; Lepine JP; Potkin SG; Vermeulen A
    Schizophr Bull; 2010 May; 36(3):504-9. PubMed ID: 18723840
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Measuring social functioning with the personal and social performance scale in patients with acute symptoms of schizophrenia: interpretation of results of a pooled analysis of three Phase III trials of paliperidone extended-release tablets.
    Patrick DL; Burns T; Morosini P; Gagnon DD; Rothman M; Adriaenssen I
    Clin Ther; 2010 Feb; 32(2):275-92. PubMed ID: 20206786
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Food and Drug Administration commentary on methodological issues in negative symptom trials.
    Laughren T; Levin R
    Schizophr Bull; 2011 Mar; 37(2):255-6. PubMed ID: 21245124
    [No Abstract]   [Full Text] [Related]  

  • 4. Methodological issues in negative symptom trials.
    Marder SR; Daniel DG; Alphs L; Awad AG; Keefe RS
    Schizophr Bull; 2011 Mar; 37(2):250-4. PubMed ID: 21270473
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Placebo washout in trials of antipsychotic drugs.
    Volavka J; Cooper TB; Laska EM; Meisner M
    Schizophr Bull; 1996; 22(4):567-76. PubMed ID: 8938911
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exploratory analyses of efficacy data from schizophrenia trials in support of new drug applications submitted to the US Food and Drug Administration.
    Khin NA; Chen YF; Yang Y; Yang P; Laughren TP
    J Clin Psychiatry; 2012 Jun; 73(6):856-64. PubMed ID: 22687813
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy for Psychopathology and Body Weight and Safety of Topiramate-Antipsychotic Cotreatment in Patients With Schizophrenia Spectrum Disorders: Results From a Meta-Analysis of Randomized Controlled Trials.
    Correll CU; Maayan L; Kane J; Hert MD; Cohen D
    J Clin Psychiatry; 2016 Jun; 77(6):e746-56. PubMed ID: 27337425
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Control group bias in randomized atypical antipsychotic medication trials for schizophrenia.
    Woods SW; Gueorguieva RV; Baker CB; Makuch RW
    Arch Gen Psychiatry; 2005 Sep; 62(9):961-70. PubMed ID: 16143728
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Definitions of response and remission in schizophrenia: recommendations for their use and their presentation.
    Leucht S; Davis JM; Engel RR; Kissling W; Kane JM
    Acta Psychiatr Scand Suppl; 2009; (438):7-14. PubMed ID: 19132961
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Asenapine in the treatment of negative symptoms of schizophrenia: clinical trial design and rationale.
    Alphs L; Panagides J; Lancaster S
    Psychopharmacol Bull; 2007; 40(2):41-53. PubMed ID: 17514185
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetic-pharmacodynamic modeling of antipsychotic drugs in patients with schizophrenia Part I: the use of PANSS total score and clinical utility.
    Pilla Reddy V; Kozielska M; Suleiman AA; Johnson M; Vermeulen A; Liu J; de Greef R; Groothuis GM; Danhof M; Proost JH
    Schizophr Res; 2013 May; 146(1-3):144-52. PubMed ID: 23473810
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Response to Shen J, Kobak K, Zhao Y, et al. Use of remote centralized raters via live 2-way video ina multicenter clinical trial for schizophrenia. (J Clin Psychopharmacol. 2008;28:691-693).
    Grunze HC; Höschl C; Montgomery SA; Sartorius N; Vieta E
    J Clin Psychopharmacol; 2009 Aug; 29(4):409; author reply 409-10. PubMed ID: 19593194
    [No Abstract]   [Full Text] [Related]  

  • 13. Meta-analyses of the efficacy of asenapine for acute schizophrenia: comparisons with placebo and other antipsychotics.
    Szegedi A; Verweij P; van Duijnhoven W; Mackle M; Cazorla P; Fennema H
    J Clin Psychiatry; 2012 Dec; 73(12):1533-40. PubMed ID: 23290326
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparing symptom response among antipsychotic medications in CATIE.
    Levine SZ; Rabinowitz J; Ascher-Svanum H; Faries DE; Lawson AH
    J Clin Psychopharmacol; 2013 Feb; 33(1):123-6. PubMed ID: 23288232
    [No Abstract]   [Full Text] [Related]  

  • 15. Efficacy and Safety of Antidepressants Added to Antipsychotics for Schizophrenia: A Systematic Review and Meta-Analysis.
    Helfer B; Samara MT; Huhn M; Klupp E; Leucht C; Zhu Y; Engel RR; Leucht S
    Am J Psychiatry; 2016 Sep; 173(9):876-86. PubMed ID: 27282362
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The PANSS should be rescaled.
    Leucht S; Kissling W; Davis JM
    Schizophr Bull; 2010 May; 36(3):461-2. PubMed ID: 20357133
    [No Abstract]   [Full Text] [Related]  

  • 18. Subjecting meta-analyses to closer scrutiny: Little support for differential efficacy among second-generation antipsychotics at equivalent doses.
    Tandon R; Nasrallah HA
    Arch Gen Psychiatry; 2006 Aug; 63(8):935-7; author reply 937-9. PubMed ID: 16894070
    [No Abstract]   [Full Text] [Related]  

  • 19. Prediction of the outcome of a phase 3 clinical trial of an antischizophrenic agent (quetiapine fumarate) by simulation with a population pharmacokinetic and pharmacodynamic model.
    Kimko HC; Reele SS; Holford NH; Peck CC
    Clin Pharmacol Ther; 2000 Nov; 68(5):568-77. PubMed ID: 11103759
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dropout rates in placebo-controlled and active-control clinical trials of antipsychotic drugs: a meta-analysis.
    Kemmler G; Hummer M; Widschwendter C; Fleischhacker WW
    Arch Gen Psychiatry; 2005 Dec; 62(12):1305-12. PubMed ID: 16330718
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.